# Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

> **NCT03716856** · PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 11 (actual)

## Conditions studied

- Refractory or Relapsed Multiple Myeloma

## Interventions

- **GENETIC:** CAR-BCMA T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03716856
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-23
- **Primary completion:** 2020-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03716856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03716856, "Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03716856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*